Headlines about Dova Pharmaceuticals (NASDAQ:DOVA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dova Pharmaceuticals earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.733238665935 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have effected Accern’s analysis:
Dova Pharmaceuticals (NASDAQ DOVA) opened at $30.37 on Tuesday. Dova Pharmaceuticals has a 52 week low of $16.98 and a 52 week high of $33.22. The firm has a market cap of $779.07 and a price-to-earnings ratio of -30.68.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same period last year, the company earned ($0.41) EPS. equities analysts anticipate that Dova Pharmaceuticals will post -1.51 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on DOVA. BidaskClub raised shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 13th. Jefferies Group lifted their target price on shares of Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Finally, Zacks Investment Research raised shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Dova Pharmaceuticals has a consensus rating of “Buy” and an average price target of $32.75.
COPYRIGHT VIOLATION WARNING: “Dova Pharmaceuticals (DOVA) Earning Somewhat Positive Press Coverage, Accern Reports” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/06/dova-pharmaceuticals-dova-earning-somewhat-positive-press-coverage-accern-reports.html.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.